Table 1.
Patient demographics and tumor characteristics of KRAS mutant cohorts.
| HES1 (+) (n = 12) | HES1 (−) (n = 14) | P value | ||
|---|---|---|---|---|
| Age | ≥ 60y | 7 (58.3%) | 10 (71.4%) | 0.683 |
| < 60y | 5 (41.7%) | 4 (28.6%) | ||
| Sex | Male | 7 (58.3%) | 9 (64.3%) | 1.000 |
| Female | 5 (41.7%) | 5 (35.7%) | ||
| Size | ≥ 5 cm | 4 (33.3%) | 8 (57.1%) | 0.267 |
| < 5 cm | 8 (66.7%) | 6 (42.9%) | ||
| Location | Left | 8 (66.7%) | 10 (71.4%) | 1.000 |
| Right | 4 (33.3%) | 4 (28.6%) | ||
| Differentiation | Low grade | 8 (66.7%) | 11 (78.6%) | 0.665 |
| High grade | 4 (33.3%) | 3 (21.4%) | ||
| Infiltration depth | T1/T2 | 2 (16.7%) | 2 (14.3%) | 1.000 |
| T3/T4 | 10 (83.3%) | 12 (85.7%) | ||
| Lymph nodes | Positive | 4 (33.3%) | 7 (50.0%) | 0.453 |
| Negative | 8 (66.7%) | 7 (50.0%) | ||
| Distant metastasis | Positive | 2 (16.7%) | 6 (42.9%; 3 synchronous liver metastases) | 0.216 |
| Negative | 10 (83.3%) | 8 (57.1%) | ||
| KRAS | G12A | 4 (33.3%) | 4 (28.6%) | |
| G12C | 0 (0.0%) | 2 (14.3%) | ||
| G12S | 0 (0.0%) | 1 (7.1%) | ||
| G12V | 3 (25.0%) | 4 (28.6%) | ||
| G13A | 4 (33.3%) | 2 (14.3%) | ||
| G61A | 1 (8.3%) | 0 (0.0%) | ||
| G61H | 0 (0.0%) | 1 (7.1%) | ||
| APC | Frameshift mutation | 10 (83.3%) | 7 (50.0%) | |
| Nonsense mutation | 5 (41.7%) | 11 (78.6%) |